DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load
This is the first study that inspected DNA methylation patterns in the molecular and clinical data with regards to cancer immunotherapy. As a result, we suggest that as an important predictive marker in immunotherapy, genomic demethylation implicates epigenetic modulation as a combination regimen for precision immunotherapy.
DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load
Global methylation loss correlated with immune evasion signatures independently of mutation burden and aneuploidy. Methylome data of our cohort ( n = 60) and a published cohort ( n = 81) in lung cancer and a melanoma cohort ( n = 40) consistently demonstrated that genomic methylation alterations counteract the contribution of high mutation burden... See more
DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load
In particular, antibody-mediated interventions targeting cytotoxic T lymphocyte antigen-4 (CTLA-4) and programmed death receptor-1 (PD-1) on T lymphocytes and the principal ligand (PD-L1) on tumour cells can reverse tumour-induced immunosuppression and induce durable clinical responses1.
DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load
employing previously defined locations of PMDs and HMDs per 100 kb16, we merged consecutive domains of the same type and retained those >300 kb in length. After assigning average methylation variability and replication timing from normal samples into each merged PMD
DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load
hiiii
mRNA expression of gene Y ~ β1 × global methylation level + β2 × mutation burden + β3 × aneuploidy level + β4 × tumour purity + β5 × age + β6 × tumour stage